Reducing pathogenic bacteria and symptoms during adult recurrent tonsillitis

Adult recurrent tonsillitis remains an important unmet clinical need in developed healthcare systems, driving repeated antibiotic use, impaired quality of life, and limited preventive options short of surgery. Many adults experience frequent relapses despite guideline-based therapy, highlighting the need for microbiome-targeted support. Recent clinical evidence from Bil B.N. et al. demonstrates that Bactoblis Adult supports faster clinical recovery, improves laboratory markers, enhances local IgA-mediated immunity, and reduces recurrence during follow-up. Bactoblis Adult uniquely combines Streptococcus salivarius K12 for oropharyngeal microbiome balance with Lactobacillus paracasei 431. Together, this dual-action approach addresses both local and systemic contributors to recurrent tonsillitis, offering adults a scientifically grounded, non-surgical strategy to help break the cycle of recurrence.

Methods and Materials
Aim of the studyTo evaluate the impact of combination probiotic treatment (SsK12 and L. paracasei 431) with bacterial tonsillitis during the acute infection and after 6 months follow-up.
Study typeRandomized, controlled, parallel-group study was conduct- ed at the ENT Department of Kyiv City Clinical Hospital.
PatientsThe study included 56 patients aged 18–57 years (mean age 32±7.5 years), including 30 women and 26 men.
Description
  • Adults diagnosed with recurrent tonsillitis 3–5 episodes annually over the past 2 years, or ≥ 3 annual episodes over the past 3 years).
  • All participants received concomitant antibiotic therapy (penicillin-clavulanate, macrolides).
  • Patients recruited during an acute RTi episode and strati- fied by McIsaac criteria for bacterial infection.
Method
  • All patients underwent standard ENT examination and laboratory testing at baseline and at 7 days after starting probiotic treatment.
  • Total follow-up duration was 180 days.
Treatment

Daily Bactoblis Adult lozenge for 30 days followed by 90 days without treatment followed by a second 30 day course of combined probiotic treatment.

XXXX

Clinical Evidence
chart 1
chart 2
Results
  • Statistically significant decrease in laboratory biomarkers of bacterial infection in Bactoblis Adult group treated patients compared to Untreated Control after 7 days treatment.
  • Significant increase after 6 month follow up in salivary IgA following Bactoblis Adult treatment (54.8 μg/mL baseline to 98.9 μg/mL post-treatment).
  • No recurrent tonsillitis episodes were recorded in the Bactoblis Adult group whereas 6 cases (21 %) occurred in the Untreated Control group after 6 months follow-up.
  • The 7 bacterial species detected on tonsil smear before treatment were reduced to 1 bacterial species after repeated course of Bactoblis Adult
Conclusion

Use of the dietary supplement Bactoblis Adult in adults with recurrent and relapsing tonsillitis was associated with accelerated clinical and laboratory recovery during acute episodes, maintenance of a healthy oropharyngeal micro- biome, enhancement of local immunity through increased secretory IgA, and prevention of recurrent tonsillitis during the observation period.

Reference/s

Bin BL et al.; Experience with the Use of the Respiratory Probiotic Bactoblis Adult in the Comprehensive Management of Recurrent and Relapsing Tonsillitis; OTORHINOLARYNGOLOGY STUDY RESULTS No. 16 (602), 2025; 

Bertuccioli A et al.; Use of Streptococcus salivarius K12 in supporting the mucosal immune function of active young subjects: A randomised double- blind study; Frontiers Immunology, 2023; 

Jespersen L et al.; Effect of Lactobacillus paracasei subsp. paracasei, L. casei 431 on immune response to influenza vaccination and upper respiratory tract infections in healthy adult volunteers: a randomized, double-blind, placebo-controlled, parallel-group study; Am J Clin Nutr, 2015